<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><description>It takes nothing to join the crowd, but it takes everything to stand alone</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 26 May 2021 07:29:09 +0800</pubDate><image><url>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</url><title>行舟Drug | wechat-feeds</title><link>http://MzUxNTM5MDcwMA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>肺癌抗血管生成药物大盘点</title><link>https://mp.weixin.qq.com/s/TXGj-JXd57fk-mPQJfUl9w</link><description></description><content:encoded><![CDATA[肺癌抗血管生成药物大盘点]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>一文讲透美国DMF</title><link>https://mp.weixin.qq.com/s/ZhnGHxZZXPLynRk9kmTmnA</link><description></description><content:encoded><![CDATA[一文讲透美国DMF]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>什么是生物制品批签发？</title><link>https://mp.weixin.qq.com/s/B-bvUCtQBP9l86dVFXayLw</link><description></description><content:encoded><![CDATA[什么是生物制品批签发？]]></content:encoded><pubDate>Tue, 25 May 2021 21:33:27 +0800</pubDate></item><item><title>谈谈中国的CAR-T发展</title><link>https://mp.weixin.qq.com/s/ZWimvyZqzX89nmM4n9WUDQ</link><description></description><content:encoded><![CDATA[谈谈中国的CAR-T发展]]></content:encoded><pubDate>Mon, 24 May 2021 21:59:07 +0800</pubDate></item><item><title>2021生物制品工艺开发及放大实战培训班</title><link>https://mp.weixin.qq.com/s/9xXsiDUaiYKbY0IYGYh3JQ</link><description></description><content:encoded><![CDATA[2021生物制品工艺开发及放大实战培训班]]></content:encoded><pubDate>Mon, 24 May 2021 21:59:07 +0800</pubDate></item><item><title>美欧日复杂注射剂技术要求及案例分析</title><link>https://mp.weixin.qq.com/s/qU7M45eFFyOib5jeb4mTPQ</link><description></description><content:encoded><![CDATA[美欧日复杂注射剂技术要求及案例分析]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>CDE-CTD共性问题汇总及解答</title><link>https://mp.weixin.qq.com/s/r9BEe_va51EfDG_0QEpmvA</link><description></description><content:encoded><![CDATA[CDE-CTD共性问题汇总及解答]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>疫苗临床开发和注册中的毒性研究</title><link>https://mp.weixin.qq.com/s/jBAqzoDKSqCCJI9s3OqMzw</link><description></description><content:encoded><![CDATA[疫苗临床开发和注册中的毒性研究]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>高端制剂是改良型新药的最优解</title><link>https://mp.weixin.qq.com/s/7i1e4hsYQwEpX4i0epupkA</link><description></description><content:encoded><![CDATA[高端制剂是改良型新药的最优解]]></content:encoded><pubDate>Sun, 23 May 2021 22:20:56 +0800</pubDate></item><item><title>2020年版药典相关问题的解读（一）</title><link>https://mp.weixin.qq.com/s/Y-rmiBFlwdizT5ZEIDMcyA</link><description></description><content:encoded><![CDATA[2020年版药典相关问题的解读（一）]]></content:encoded><pubDate>Sat, 22 May 2021 20:21:59 +0800</pubDate></item><item><title>吴一龙教授 | 引领肺癌治疗新时代的标志物-微小残留病灶</title><link>https://mp.weixin.qq.com/s/uOiZBh0a3LkiMxKITw311w</link><description></description><content:encoded><![CDATA[吴一龙教授 | 引领肺癌治疗新时代的标志物-微小残留病灶]]></content:encoded><pubDate>Sat, 22 May 2021 20:21:59 +0800</pubDate></item><item><title>【大力推荐】《已上市化学药品药学变更研究技术指导原则（试行）》解读-答疑</title><link>https://mp.weixin.qq.com/s/Xof9MgDKyUcYMKbcgnrGTQ</link><description></description><content:encoded><![CDATA[【大力推荐】《已上市化学药品药学变更研究技术指导原则（试行）》解读-答疑]]></content:encoded><pubDate>Sat, 22 May 2021 20:21:59 +0800</pubDate></item><item><title>一文看懂进口药品跨境电商试点</title><link>https://mp.weixin.qq.com/s/vqoF70QlwtfqeUT1ClZvJw</link><description></description><content:encoded><![CDATA[一文看懂进口药品跨境电商试点]]></content:encoded><pubDate>Sat, 22 May 2021 20:21:59 +0800</pubDate></item><item><title>ADCs药物申报IND/NDA的药学审评要点</title><link>https://mp.weixin.qq.com/s/kDNk56gnyrl1PUgBFGkLyg</link><description></description><content:encoded><![CDATA[ADCs药物申报IND/NDA的药学审评要点]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>中美欧——变更对比（CDE首席科学家解读PACMP）</title><link>https://mp.weixin.qq.com/s/OTE4ZG56aEYxxQyC-QXIGg</link><description></description><content:encoded><![CDATA[中美欧——变更对比（CDE首席科学家解读PACMP）]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>超滤在生物医药领域的应用</title><link>https://mp.weixin.qq.com/s/ehhYX5Aexao063Mb3_RpnQ</link><description></description><content:encoded><![CDATA[超滤在生物医药领域的应用]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>FDA药物稳定性试验指导原则中文版</title><link>https://mp.weixin.qq.com/s/Bnac6FHtjO4JjUMZLe5DXQ</link><description></description><content:encoded><![CDATA[FDA药物稳定性试验指导原则中文版]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>药物研究中制剂有关物质研究的重点及策略</title><link>https://mp.weixin.qq.com/s/ziWgdUUtVeHSpVuRqb5aqA</link><description></description><content:encoded><![CDATA[药物研究中制剂有关物质研究的重点及策略]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>仿制药研发流程-质量研究详细讲解</title><link>https://mp.weixin.qq.com/s/pjJFNr-zwOtdXFrsqg-w8g</link><description></description><content:encoded><![CDATA[仿制药研发流程-质量研究详细讲解]]></content:encoded><pubDate>Fri, 21 May 2021 19:14:14 +0800</pubDate></item><item><title>基于FDA 工艺验证指南&amp;PDA TR60的全生命周期工艺验证</title><link>https://mp.weixin.qq.com/s/85Cv6RZm82Rx6KvvZkLAtw</link><description></description><content:encoded><![CDATA[基于FDA 工艺验证指南&PDA TR60的全生命周期工艺验证]]></content:encoded><pubDate>Thu, 20 May 2021 19:28:57 +0800</pubDate></item></channel></rss>